Abivax SA (Euronext Paris: ABVX.PA) is developing novel therapies to treat serious infectious diseases. The Company’s lead product candidate, ABX203, is a therapeutic vaccine to treat hepatitis B. Abivax has completed enrollment for a Phase II/III trial evaluating ABX203 and expects to report topline data in the fourth quarter of 2016. Abivax is also evaluating ABX464 as a potential treatment for HIV. Phase IIa data for this program was recently presented showing a dose-dependent reduction in viral load with no indications of drug resistance. The Company plans to conduct a second Phase IIa trial with ABX464 to test the durability of the drug’s effect.